Summit Therapeutics said the FDA issued a Complete Response Letter (CRL) for ivonescimab in non-small cell lung cancer, saying the application cannot be approved in its present form without a statistically significant overall survival improvement.
SMMT · Summit Therapeutics Inc.
The latest filing no longer states the doubt (first flagged Jul 23, 2026).
View the 10-Q filed Nov 4, 2026You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Summit Therapeutics Inc.’s prospectus supplement covers resale of up to 108,955,369 common shares issuable on preferred-stock conversion; Baker & Hostetler LLP opined they will be validly issued, fully paid and nonassessable.
Summit Therapeutics’ ivonescimab BLA was accepted in January 2026, with an FDA action date of November 14, 2026. A June 2026 analysis showed an OS hazard ratio of 0.76 (nominal p=0.0151), but FDA requires a statistically significant OS benefit.
Summit Therapeutics reported third-quarter results ended September 30, 2026, with $629.8 million cash and investments, a $2.0 billion AstraZeneca investment, an FDA PDUFA goal action date of November 14, 2026 for ivonescimab, and a HARMONi overall-survival hazard ratio of 0.76.
Summit Therapeutics is holding a virtual special meeting on November 4, 2026 at 11:00 a.m. Eastern Time to seek stockholder approval of an amendment increasing authorized common stock from 1,000,000,000 to 2,000,000,000 shares.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SMMT
this stock
Summit Therapeutics Inc.
|
$9.45B | -32.4% | — | — | 5.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.35B | +18.6% | +46.2% | 34.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.52B | +23.4% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$87.10B | +630.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.26B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 32
Summit Therapeutics said the FDA issued a Complete Response Letter (CRL) for ivonescimab in non-small cell lung cancer, saying the application cannot be approved in its present form without a statistically significant overall survival improvement.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SMMT | -33.7% | -24.1% | -31.9% | -26.3% | -32.4% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -32.1% | -20.6% | -30.5% | -24.2% | -40.9% |